Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$28.90 -3.9%	$27.12	$15.35 ▼ $36.44	$2.97B	2.26	2.03 million shs	2.05 million shs
BLBD Blue Bird	$63.47 +0.9%	$58.78	$36.01 ▼ $66.13	$2.01B	1.38	409,173 shs	293,338 shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $5.03	$48.67M	0.27	807,956 shs	N/A
CRSP CRISPR Therapeutics	$52.38 -2.2%	$52.43	$33.03 ▼ $78.48	$5.05B	1.75	1.89 million shs	3.10 million shs
NTLA Intellia Therapeutics	$13.31 -4.0%	$13.62	$6.83 ▼ $28.25	$1.57B	1.93	5.35 million shs	4.87 million shs
NVDA NVIDIA	$196.48 -1.0%	$186.75	$110.82 ▼ $216.82	$4.77T	2.25	171.29 million shs	111.12 million shs
VRTX Vertex Pharmaceuticals	$424.36 -1.3%	$453.82	$362.50 ▼ $507.92	$107.94B	0.3	1.40 million shs	1.91 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+5.30%	+24.55%	+10.13%	+51.75%
BLBD Blue Bird	0.00%	-2.47%	+7.23%	+19.89%	+65.58%
BLUE bluebird bio	0.00%	0.00%	0.00%	0.00%	+25.82%
CRSP CRISPR Therapeutics	0.00%	+1.26%	+4.28%	-0.71%	+34.98%
NTLA Intellia Therapeutics	0.00%	+1.89%	+0.99%	+1.61%	+50.00%
NVDA NVIDIA	0.00%	-8.38%	+11.87%	+10.04%	+73.32%
VRTX Vertex Pharmaceuticals	0.00%	-0.49%	-3.37%	-8.95%	-15.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$28.90 -3.9%	$27.12	$15.35 ▼ $36.44	$2.97B	2.26	2.03 million shs	2.05 million shs
BLBD Blue Bird	$63.47 +0.9%	$58.78	$36.01 ▼ $66.13	$2.01B	1.38	409,173 shs	293,338 shs
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $5.03	$48.67M	0.27	807,956 shs	N/A
CRSP CRISPR Therapeutics	$52.38 -2.2%	$52.43	$33.03 ▼ $78.48	$5.05B	1.75	1.89 million shs	3.10 million shs
NTLA Intellia Therapeutics	$13.31 -4.0%	$13.62	$6.83 ▼ $28.25	$1.57B	1.93	5.35 million shs	4.87 million shs
NVDA NVIDIA	$196.48 -1.0%	$186.75	$110.82 ▼ $216.82	$4.77T	2.25	171.29 million shs	111.12 million shs
VRTX Vertex Pharmaceuticals	$424.36 -1.3%	$453.82	$362.50 ▼ $507.92	$107.94B	0.3	1.40 million shs	1.91 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+5.30%	+24.55%	+10.13%	+51.75%
BLBD Blue Bird	0.00%	-2.47%	+7.23%	+19.89%	+65.58%
BLUE bluebird bio	0.00%	0.00%	0.00%	0.00%	+25.82%
CRSP CRISPR Therapeutics	0.00%	+1.26%	+4.28%	-0.71%	+34.98%
NTLA Intellia Therapeutics	0.00%	+1.89%	+0.99%	+1.61%	+50.00%
NVDA NVIDIA	0.00%	-8.38%	+11.87%	+10.04%	+73.32%
VRTX Vertex Pharmaceuticals	0.00%	-0.49%	-3.37%	-8.95%	-15.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.75	Moderate Buy	$49.36	70.79% Upside
BLBD Blue Bird	2.86	Moderate Buy	$67.20	5.88% Upside
BLUE bluebird bio	0.00	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$64.53	23.19% Upside
NTLA Intellia Therapeutics	2.35	Hold	$20.09	50.92% Upside
NVDA NVIDIA	3.04	Buy	$275.25	40.09% Upside
VRTX Vertex Pharmaceuticals	2.83	Moderate Buy	$554.83	30.74% Upside

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2026	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$612.00 ➝ $616.00
5/5/2026	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$541.00 ➝ $543.00
5/5/2026	VRTX Vertex Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$577.00 ➝ $572.00
5/5/2026	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$437.00 ➝ $436.00
4/30/2026	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$441.00 ➝ $437.00
4/28/2026	NTLA Intellia Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sell	$8.00 ➝ $9.00
4/28/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
4/28/2026	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$48.00 ➝ $58.00
4/28/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$28.00 ➝ $30.00
4/27/2026	NTLA Intellia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
4/27/2026	NTLA Intellia Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$11.00 ➝ $15.00

(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	21.25	N/A	N/A	$12.20 per share	2.37
BLBD Blue Bird	$1.50B	1.34	$4.75 per share	13.37	$8.06 per share	7.87
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	$20.17 per share	N/A
NTLA Intellia Therapeutics	$67.67M	23.24	N/A	N/A	$5.80 per share	2.29
NVDA NVIDIA	$215.94B	22.11	$4.68 per share	42.01	$6.47 per share	30.37
VRTX Vertex Pharmaceuticals	$12.00B	8.99	$17.59 per share	24.12	$73.57 per share	5.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$1.01	N/A	N/A	N/A	-57.24%	-30.65%	-23.73%	5/5/2026 (Estimated)
BLBD Blue Bird	$127.72M	$3.96	16.03	12.57	2.34	8.65%	57.60%	22.66%	5/6/2026 (Estimated)
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	N/A
CRSP CRISPR Therapeutics	-$581.60M	-$6.52	N/A	N/A	N/A	-16,569.77%	-26.31%	-22.30%	5/11/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.83	N/A	N/A	N/A	-609.85%	-56.81%	-45.34%	5/14/2026 (Estimated)
NVDA NVIDIA	$120.07B	$4.90	40.10	18.69	0.65	55.60%	97.37%	70.68%	5/20/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$15.33	27.68	22.29	1.84	32.94%	24.30%	17.38%	N/A

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2026	Q1 2027	NVDA NVIDIA	$1.76	N/A	N/A	N/A	$78.42 billion	N/A
5/14/2026	Q1 2026	NTLA Intellia Therapeutics	-$0.92	N/A	N/A	N/A	$13.81 million	N/A
5/11/2026	Q1 2026	CRSP CRISPR Therapeutics	-$1.2227	-$1.28	-$0.0573	-$1.28	$6.06 million	$1.46 million
5/6/2026	Q2 2026	BLBD Blue Bird	$0.8680	N/A	N/A	N/A	$335.23 million	N/A
5/5/2026	Q1 2026	BEAM Beam Therapeutics	-$1.0278	N/A	N/A	N/A	$10.98 million	N/A
5/4/2026	Q1 2026	VRTX Vertex Pharmaceuticals	$4.24	$4.47	+$0.23	$4.02	$2.99 billion	$2.99 billion
2/26/2026	Q4 2025	NTLA Intellia Therapeutics	-$0.99	-$0.83	+$0.16	-$0.83	$12.17 million	$23.02 million
2/25/2026	Q4 2026	NVDA NVIDIA	$1.54	$1.62	+$0.08	$1.76	$65.56 billion	$68.13 billion
2/24/2026	Q4 2025	BEAM Beam Therapeutics	-$1.13	$2.33	+$3.46	$2.33	$13.22 million	$114.11 million
2/13/2026	Q4 2025	CRSP CRISPR Therapeutics	-$1.15	-$1.37	-$0.22	-$1.37	$4.72 million	$0.86 million
2/12/2026	Q4 2025	VRTX Vertex Pharmaceuticals	$5.05	$5.03	-$0.02	$4.65	$3.18 billion	$3.19 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.11%	N/A	N/A	N/A
BLBD Blue Bird	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NVDA NVIDIA	$0.04	0.02%	+14.87%	0.82%	1 Years
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/25/2026	NVDA NVIDIA	quarterly	$0.01	0.02%	3/11/2026	3/11/2026	4/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	13.09	13.09
BLBD Blue Bird	0.31	1.81	1.21
BLUE bluebird bio	0.37	0.51	0.33
CRSP CRISPR Therapeutics	N/A	13.32	13.32
NTLA Intellia Therapeutics	N/A	5.08	5.08
NVDA NVIDIA	0.05	3.91	3.24
VRTX Vertex Pharmaceuticals	N/A	2.90	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
BLBD Blue Bird	93.59%
BLUE bluebird bio	87.43%
CRSP CRISPR Therapeutics	69.20%
NTLA Intellia Therapeutics	88.77%
NVDA NVIDIA	65.27%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
BLBD Blue Bird	1.10%
BLUE bluebird bio	1.40%
CRSP CRISPR Therapeutics	4.30%
NTLA Intellia Therapeutics	3.10%
NVDA NVIDIA	4.17%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	102.75 million	98.84 million	Optionable
BLBD Blue Bird	2,012	31.59 million	31.24 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CRSP CRISPR Therapeutics	460	96.43 million	92.48 million	Optionable
NTLA Intellia Therapeutics	600	118.13 million	114.47 million	Optionable
NVDA NVIDIA	42,000	24.30 billion	23.29 billion	Optionable
VRTX Vertex Pharmaceuticals	6,400	254.36 million	253.85 million	Optionable

CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Headlines

Recent News About These Companies

Promising Biotech Stocks To Watch Today - May 5th

3 hours ago | marketbeat.com

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings

3 hours ago | benzinga.com

VRTX's Q1 Earnings Beat Estimates, New Products Aid Sales Growth

3 hours ago | zacks.com

Vertex Pharmaceuticals Posts Mixed Q1; Investors Focus On Non-CF Pipeline For Growth

May 5 at 12:11 PM | benzinga.com

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

May 5 at 9:21 AM | zacks.com

Varma Mutual Pension Insurance Co Grows Stake in Vertex Pharmaceuticals Incorporated $VRTX

May 5 at 8:34 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated Q1 2026 Earnings Call Summary

May 5 at 7:55 AM | app.moby.coA

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Truist Financial Corp

May 5 at 6:40 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript

May 4 at 12:00 AM | seekingalpha.com

Vertex Pharmaceuticals Earnings Call Highlights New Growth Engines

May 4 at 8:31 PM | tipranks.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations

May 4 at 8:08 PM | finance.yahoo.com

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates

May 4 at 8:08 PM | finance.yahoo.com

Vertex Dips On Mixed First-Quarter Report; But There's A Silver Lining

May 4 at 8:08 PM | finance.yahoo.com

Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say

May 4 at 8:08 PM | finance.yahoo.com

Vertex (VRTX) Q1 2026 Earnings Call Transcript

May 4 at 8:08 PM | fool.com

Vertex Pharmaceuticals Q1 Earnings Call Highlights

May 4 at 8:07 PM | marketbeat.com

Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say

May 4 at 7:01 PM | zacks.com

Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Beats Estimates By $0.24 EPS

May 4 at 6:41 PM | marketbeat.com

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates

May 4 at 6:20 PM | zacks.com

Vertex Pharmaceuticals Reports Mixed Q1 Results

May 4 at 5:31 PM | benzinga.com

Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings

May 4 at 4:50 PM | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$28.90 -1.18 (-3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$29.30 +0.40 (+1.37%)

As of 05:44 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Blue Bird NASDAQ:BLBD

$63.47 +0.58 (+0.92%)

Closing price 03:59 PM Eastern

Extended Trading

$63.43 -0.04 (-0.06%)

As of 04:53 PM Eastern

Blue Bird Corporation, together with its subsidiaries, designs, engineers, manufactures, and sells school buses in the United States, Canada, and internationally. The company operates through two segments, Bus and Parts. It offers Type C, Type D, and specialty buses; and alternative power options through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. The company also sells replacement bus parts; and provides financing services and extended warranties related to its products. Blue Bird Corporation sells its products through drop ship and a network of dealers, as well as directly to fleet operators, the United States government, and state governments; independent service centers; and maintains a parts distribution center. Blue Bird Corporation was founded in 1927 and is headquartered in Macon, Georgia.

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$52.38 -1.20 (-2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$52.30 -0.08 (-0.15%)

As of 05:43 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Intellia Therapeutics NASDAQ:NTLA

$13.31 -0.56 (-4.04%)

Closing price 04:00 PM Eastern

Extended Trading

$13.36 +0.05 (+0.37%)

As of 05:44 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NVIDIA NASDAQ:NVDA

$196.48 -2.00 (-1.01%)

Closing price 03:59 PM Eastern

Extended Trading

$197.11 +0.63 (+0.32%)

As of 05:45 PM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Vertex Pharmaceuticals NASDAQ:VRTX

$424.36 -5.49 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$419.54 -4.82 (-1.14%)

As of 05:45 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Earnings

Compare Dividends

Latest CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRSP, VRTX, NTLA, BEAM, BLBD, BLUE, and NVDA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Blue Bird NASDAQ:BLBD

bluebird bio NASDAQ:BLUE

CRISPR Therapeutics NASDAQ:CRSP

Intellia Therapeutics NASDAQ:NTLA

NVIDIA NASDAQ:NVDA

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools